Market Overview:
The global cemiplimab-rwlc market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cancer, rising demand for targeted therapies, and growing investments by pharmaceutical companies in R&D for novel oncology drugs. Based on type, the global cemiplimab-rwlc market is segmented into 10MIU /vial, 18MIU /vial, and 25MIU /vial. Based on application, the market is segmented into hospital and drug store. Geographically, the global cemiplimab-rwlc market is segmented into North America, Latin America, Europe Asia Pacific , and Middle East & Africa .
Product Definition:
Cemiplimab-rwlc is a human monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1, thereby releasing the brakes on T cell activation. Cemiplimab has been shown to induce tumor regression in preclinical models of cancer.
10MIU /Vial:
10MIU is the concentration of a drug that can be mixed with an appropriate solvent to make a solution having the same concentration as that of original drug. It is used for measuring the amount of protein in biological fluids such as blood, serum, and plasma.
The 10 MIU/Vial refers to vials containing 0.1 ml each of solvents (D5W) and Cremophor Solution (QF).
18MIU /Vial:
18MIU is the unitary measure for cemiplimab-rwlc in the European market. It is defined as the amount of drug substance (active pharmaceutical ingredient) contained in one vial which gives 1/1000th of a kg of finished product. The 18 MIU /Vial contains 0.3 kgs (6 mg)of cemiplimab-rwlc, manufactured by Grifols, Spain and was approved by EU commission in 2017.
Application Insights:
The global market is segmented by application into hospital, drug store and others. The hospital segment dominated the overall market in terms of revenue share in 2017. This can be attributed to the growing usage of cemiplimab-rwlc for various indications such as cancer, rheumatoid arthritis and other autoimmune diseases.
Cancer is one of the most common causes leading to death worldwide due to its high cost associated with it which cannot be covered by insurance companies. According to data published by WHO, an estimated 9 million people die due to cancer every year globally which accounts for around 22% of all deaths globally every year thus emphasizing on early diagnosis and treatment hence driving demand for cemiplimab-rwlc in hospitals across the world especially during emergencies when other drugs cannot be used or are not effective owing to its toxicity thus driving growth at a lucrative rate during this period.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and high adoption rate for advanced therapeutics are some factors responsible for its large share. In addition, increasing R&D activities to improve treatment options is also expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure and improving healthcare infrastructure in emerging countries such as China and India. Moreover, growing awareness regarding cancer treatments will also support regional growth during the estimated time span.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the cemiplimab-rwlc market. According to a study by the American Cancer Society, it is estimated that around 1,735,350 new cases of cancer will be diagnosed in the United States in 2018. This number is expected to rise to over 2 million by 2030. This growing prevalence of cancer is expected to drive demand for cemiplimab-rwlc and other anticancer drugs in the coming years.
- Rising awareness about available treatment options: The increasing awareness about available treatment options for various types of cancers is another key growth driver for the cemiplimab-rwlc market. With advances in technology and rising R&D investments, there are now several effective treatment options available for various types of cancers. This has led to an increase in demand for anticancer drugs such as cemiplimab-rwlc worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cemiplimab-rwlc Market Research Report
By Type
10MIU /Vial, 18MIU /Vial, 25MIU /Vial
By Application
Hospital, Drug Store
By Companies
Sanofi, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
152
Number of Tables & Figures
107
Customization Available
Yes, the report can be customized as per your need.
Global Cemiplimab-rwlc Market Report Segments:
The global Cemiplimab-rwlc market is segmented on the basis of:
Types
10MIU /Vial, 18MIU /Vial, 25MIU /Vial
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drug Store
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Sanofi
Highlights of The Cemiplimab-rwlc Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 10MIU /Vial
- 18MIU /Vial
- 25MIU /Vial
- By Application:
- Hospital
- Drug Store
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cemiplimab-rwlc Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cemiplimab-rwlc is a monoclonal antibody that targets the CD20 antigen on the surface of cancer cells. It is used to treat various types of cancer, including lymphoma, leukemia, and multiple myeloma.
Some of the major players in the cemiplimab-rwlc market are Sanofi, Sanofi.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cemiplimab-rwlc Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cemiplimab-rwlc Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cemiplimab-rwlc Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cemiplimab-rwlc Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cemiplimab-rwlc Market Size & Forecast, 2020-2028
4.5.1 Cemiplimab-rwlc Market Size and Y-o-Y Growth
4.5.2 Cemiplimab-rwlc Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 10MIU /Vial
5.2.2 18MIU /Vial
5.2.3 25MIU /Vial
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drug Store
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cemiplimab-rwlc Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cemiplimab-rwlc Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 10MIU /Vial
9.6.2 18MIU /Vial
9.6.3 25MIU /Vial
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drug Store
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 10MIU /Vial
10.6.2 18MIU /Vial
10.6.3 25MIU /Vial
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drug Store
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 10MIU /Vial
11.6.2 18MIU /Vial
11.6.3 25MIU /Vial
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drug Store
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 10MIU /Vial
12.6.2 18MIU /Vial
12.6.3 25MIU /Vial
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drug Store
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 10MIU /Vial
13.6.2 18MIU /Vial
13.6.3 25MIU /Vial
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drug Store
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cemiplimab-rwlc Market: Competitive Dashboard
14.2 Global Cemiplimab-rwlc Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Sanofi
